M Yadira Hurley, MD
Dermatopathology · Saint Louis, MONPI 1881611853
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Argenx US, Inc. at 56.8% of the total. Reporting peaked in 2023 at $7,129 and has fallen 77.2% since, to $1,622 in 2025.
Across 34 payments — averaging $356.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$7K
- Blueprint Medicines Corporation$2K
- Insmed, Inc.$1K
- Pfizer$637
- Novartis$293
- Biogen$246
- plus $568 from 7 others
Across 192 payments — averaging $5862.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$465K
- Argenx US, Inc.$389K
- Pfizer$106K
- AbbVie$94K
- Janssen Research & Development, LLC$63K
- Hoffmann-la Roche Limited$8K
- plus $791 from 2 others
What the payments were for
- Consulting fees$6,00050%
- Speaking & faculty fees$2,25819%
- Travel & lodging$2,45920%
- Food & beverage$1,38911%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 8 | $6,879 |
| Blueprint Medicines Corporation | 1 | $2,258 |
| Insmed, Inc. | 8 | $1,239 |
| Pfizer | 2 | $637 |
| Novartis | 2 | $293 |
| Biogen | 4 | $246 |
| Boehringer Ingelheim | 1 | $142 |
| E.r. Squibb & Sons, L.L.C. | 2 | $138 |
| Regeneron Healthcare Solutions, Inc. | 1 | $117 |
| Dermavant Sciences, Inc. | 1 | $111 |
| AbbVie | 2 | $28 |
| Roche Diagnostics Corporation | 1 | $18 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few dermatopathology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $249,903 |
| Clobetasol Propionate | 76 | $4,465 |
| Mycophenolate Mofetil | 15 | $3,001 |
| Triamcinolone Acetonide | 64 | $1,065 |
| Ketoconazole | 63 | $1,044 |
| Metronidazole | 15 | $671 |
| Clindamycin Phosphate | 15 | $602 |
| Hydrocortisone | 32 | $384 |
| Nystatin | 15 | $351 |
| Fluocinonide | 12 | $313 |
| Gabapentin | 12 | $292 |
| MethotrexateMethotrexate Sodium | 14 | $224 |
| Mupirocin | 11 | $184 |
| Prednisone | 18 | $95 |
| Fluconazole | 14 | $74 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Saint Louis
- Georgeanne CornellSaint Louis$3K
- Emily SmithSaint Louis$3K
- Kristine SmithSaint Louis$133
- Mark HurtMaryland Heights$2K
- Sarah WalshMaryland Heights$1K
- Kara LefevreColumbia$193
- William BlankChaffee$28
- Cecilia RosalesKansas City$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.